Is SLS a good stock to buy? We came across a bullish thesis on SELLAS Life Sciences Group, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SLS. SELLAS Life Sciences Group, Inc.’s share was trading at $9.07 as of June 23rd.
Pressmaster/Shutterstock.com
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. SLS is presented as a high-upside clinical-stage oncology company whose valuation is heavily anchored to near-term binary catalysts, most importantly the Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The central bullish argument is that the unusually long duration of the event-driven trial, which has reached 78 of 80 required deaths as of May 2026, is being misinterpreted by the market as delay risk rather than a signal of strong survival benefit versus historical expectations of only 5–7 months in this patient population.
With final unblinding expected after the last two events, investors see a clear path to a major re-rating once data removes the primary clinical uncertainty and potentially supports regulatory submission by late 2026. The company is also advancing SLS009, a CDK9 inhibitor showing early efficacy signals including a 46% response rate in relapsed settings, adding a second value driver beyond the lead asset.
Sellas benefits from a capital-light strategy focused on partnerships and milestone monetization, supported by strong intellectual property protection, orphan drug exclusivity in the US and Europe, and manufacturing complexity that reinforces its moat. Financially, the company holds over $107 million in cash with a runway into 2028, limiting near-term dilution risk and providing stability ahead of key readouts.
The bull case assumes successful REGAL results could justify peak penetration in an underserved AML maintenance market and drive meaningful commercial upside, while risk-adjusted valuation models support a post-data target price of $16.50 versus a current price around $7.18, implying approximately +129.8% upside. Under this scenario, Sellas is viewed as a deeply undervalued oncology opportunity where delayed trial events may ultimately translate into evidence of durable survival benefit and significant shareholder re-rating potential.
Previously, we covered a bullish thesis on Gilead Sciences, Inc. (GILD) by Disruptive analytics in February 2025, highlighting policy, currency, and COVID-related headwinds limiting near-term growth despite stable cost discipline. GILD’s stock price has appreciated by approximately 20.14% since our coverage. BioEquity Watch shares a similar view but emphasizes SELLAS Life Sciences Group, Inc. (SLS) as a catalyst-driven oncology play with Phase 3 binary outcomes and +129.8% upside.
SELLAS Life Sciences Group, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 13 hedge fund portfolios held SLS at the end of the first quarter which was 6 in the previous quarter. While we acknowledge the risk and potential of SLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
